Filing Details
- Accession Number:
- 0001104659-20-001084
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-03 19:00:51
- Reporting Period:
- 2019-12-31
- Accepted Time:
- 2020-01-03 19:00:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc. | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1761167 | Gail Cawkwell | C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001 | Svp, Med Affairs, Safety & Pv | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-12-31 | 262 | $54.63 | 18,984 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-12-31 | 262 | $125.00 | 18,722 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-12-31 | 349 | $123.92 | 18,373 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Disposition | 2019-12-31 | 262 | $0.00 | 262 | $54.63 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
20,779 | 2028-02-12 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.
- The award is subject to a four-year vesting period, with 25% of shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 12, 2018.